TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01450995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treximet
Description: Tablet form, one tablet dose, one tablet at migraine onset with second tablet for persistent or recurring migraine two hours after first dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imitrex and two Aleve
Description: Imitrex tablet, one tablet dose, Aleve tablets, 2 220 mg tablet dose. Three tablets taken concurrently with migraine onset. Second dose of tablets may be taken if migraine persists for two hours
Study: NCT03931161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab Auto-Injector [Repatha]
Description: Auto-Injector, 140 mg every two weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Auto-Injector
Description: Matching Placebo for the active comparator (Evolocumab)
Study: NCT04066023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C213 Microneedle System
Description: The C213 System is a proprietary disposable patch and a reusable applicator. The zolmitriptan-coated titanium microneedle array (3 cm\^2 array) is attached to a 5 cm\^2 adhesive patch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C213 Microneedle System
Description: The C213 System is a proprietary disposable patch and a reusable applicator. The zolmitriptan-coated titanium microneedle array (3 cm\^2 array) is attached to a 5 cm\^2 adhesive patch.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The C213 System is a proprietary disposable patch and a reusable applicator. The placebo patch is a single use, 3 cm\^2 Placebo (intracutaneous microneedle) system that contains no active ingredients.
Study: NCT01552694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Oral, 100 mg/day for 2 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, matching placebo daily for 2 months
Study: NCT01211730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.
Study: NCT01752361

Intervention type: DEVICE
Intervention: Motilis-3D transit
Study: NCT02178371

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mCIMT
Description: affected upper limb use with constraint of the healthy hand

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unimanual therapy without constraint UTWC
Description: affected upper limb use without constraint of healthy hand
Study: NCT00758836

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetominophen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: telcagepant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telcagepant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telcagepant
Study: NCT03668860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4 mg/ml
Description: Intramuscular. Total dose: 1.5 mL (6 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4 mg/ml
Description: Intramuscular. Total dose: 1.5 mL (6 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone 4 mg/ml
Description: Intramuscular. Total dose: 1.5 mL (6 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone 4 mg/ml
Description: Intramuscular. Total dose: 1.5 mL (6 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celestone Soluspan 6Mg/Ml Suspension for Injection
Description: Intramuscular. Total dose: 1 mL (6 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celestone Soluspan 6Mg/Ml Suspension for Injection
Description: Intramuscular. Total dose: 1 mL (6 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celestone Soluspan 6Mg/Ml Suspension for Injection
Description: Intramuscular. Total dose: 1 mL (6 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celestone Soluspan 6Mg/Ml Suspension for Injection
Description: Intramuscular. Total dose: 1 mL (6 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral Tablet
Description: Oral. Total dose: 12 Tablets (6 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral Tablet
Description: Oral. Total dose: 12 Tablets (6 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral Tablet
Description: Oral. Total dose: 12 Tablets (6 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral Tablet
Description: Oral. Total dose: 12 Tablets (6 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone Oral Tablet
Description: Oral. Total dose: 12 Tablets (6 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone Oral Tablet
Description: Oral. Total dose: 12 Tablets (6 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone Oral Tablet
Description: Oral. Total dose: 12 Tablets (6 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone Oral Tablet
Description: Oral. Total dose: 12 Tablets (6 mg)
Study: NCT00816595

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentostatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentostatin
Description: Given IV
Study: NCT02378259

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass
Description: Bariatric surgery with Roux-en-Y gastric bypass as preferred option, possible laparoscopic Vertical Sleeve Gastrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intense conservative treatment
Description: Intense medical treatment for obesity (behavioral treatment, dietary intervention, exercise, medication etc) 8 week period of Low Calorie Diet. Treatment intensity about 1 visit a month over 2 years
Study: NCT03815136

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group will not chew chewing gum while undergoing capsule endoscopy
Study: NCT02343029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualised aerobic exercise training
Description: During the first 4 weeks of intervention two of the three weekly training sessions are offered as group training supervised by the respective qualified exercise physiologist of the Department of Sports Medicine. After 4 weeks, participants' physical performance is reassessed at the Department of Sports Medicine. If necessary, workload is readjusted to achieve the initially defined exercise intensity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individualised aerobic exercise training
Description: During the first 4 weeks of intervention two of the three weekly training sessions are offered as group training supervised by the respective qualified exercise physiologist of the Department of Sports Medicine. After 4 weeks, participants' physical performance is reassessed at the Department of Sports Medicine. If necessary, workload is readjusted to achieve the initially defined exercise intensity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waiting Control
Description: After waiting for 12 weeks with normal daily activity, patients are allocated to a individualised aerobic exercise training, too.
Study: NCT01275287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care treatment
Description: induction : pulse methyl prednisolone (7 mg/kg/day x3) then prednisone 1 mg/kg/day (not to exceed 60 mg/day) for 4 weeks, then taper over the following 12 weeks. Cyclophosphamide starting at 0.75 gm/m2 IV (decreased to 0.5 gm/m\^2 for patients \> than 70 or with estimated Glomerular Filtration Rate (eGFR) \< 20 ml/min) to be titrated up to 1 gm/m\^2 depending on the 2 week white blood count (WBC) nadir \> 3000 cell/μL. Subsequent cyclophosphamide will be given every 4 weeks for at least 2 more doses. Once complete remission for 2 months, patient may be switched from cyclophosphamide to maintenance therapy with azathioprine 1.5-2 mg/kg/day for 6-9 months (to a total of 12 months of therapy) .~For patients who cannot tolerate cyclophosphamide, or who have received it in large doses previously, another medication called rituximab may be used instead. However, if rituximab is indicated for the patient, he cannot participate in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eculizumab
Description: In addition to conventional therapy, patients randomized to eculizumab will receive 600 mg by IV infusion over 35 minutes every 7 days for the first 4 weeks, then 900 mg by IV infusion for the fifth dose 7 days later (week 5), then 900 mg every 14 days thereafter, for a total of 9 doses (about 3 months of treatment). This dosing scheme is based on that used for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The length of treatment is shorter than for PNH, based on a desire to target the addition of eculizumab to the period of maximal disease activity, while limiting the risks of infectious complications in this first pilot study.
Study: NCT04295915

Intervention type: DEVICE
Intervention: Specimens that meet inclusion criteria
Description: Specimens that have been de-identified and considered remnant by the laboratory (fresh specimens) or were contrived by the laboratory (using bacterial isolates with no identifying information) can be enrolled into the study.
Study: NCT03825978

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prenatal Genetic Counseling
Description: In this study prenatal genetic screening counseling was provided from the begining of the pregnancy, different from the other studies in the literature. In the literature, most of the study evaluated pregnant women's anxiety, information status about the test and decisional conflicts, only prenatal screening process or prenatal diagnosis process. In this study pregnant women were evaluated both in prenatal screening test and prenatal diagnosis procedures.
Study: NCT02795052

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intravenous and Intranasal BMSC
Description: Autologous Bone Marrow Derived Stem Cells provided intravenous and intranasal (lower 1/3 of nose)
Study: NCT03406936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daily interruption of midazolam
Description: daily at 7 am midazolam infusion will be stopped spontaneous breath trial will be done
Study: NCT01622868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib Ditosylate
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiotherapy
Description: Undergo WBRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiotherapy
Description: Undergo WBRT
Study: NCT00803387

Intervention type: DRUG
Intervention: Travaprost without BAC (Travatan Z)
Description: A double blind comparison was used to assess whether Xalatan or TrvatanZ affects the tear breakup times, corneal staining, and baseline tear secretion tests in patients that are already taking latanoprost regularly with complaints of dryness and irritation. Patients included in the study will be given two bottles, one labeled for their right eye and the other for their left eye. Each pair of bottles will be identical in appearance and randomized with either latanoprost or travoprost and each pair will be assigned a number to aid in future analysis of the final results. One Drop from both bottles will be dispensed in the respective eye once a day.
Study: NCT00654589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Study: NCT03423407

Intervention type: DEVICE
Intervention: Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)
Description: FDA approved scanner
Study: NCT03303651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Opioid administration in intervention groups
Description: Elective surgery in radical open abdominal prostatectomy. Opioid titration is guided by analgesia indices during general anesthesia in the experimental arms.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Opioid administration in intervention groups
Description: Elective surgery in radical open abdominal prostatectomy. Opioid titration is guided by analgesia indices during general anesthesia in the experimental arms.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Opioid administration in intervention groups
Description: Elective surgery in radical open abdominal prostatectomy. Opioid titration is guided by analgesia indices during general anesthesia in the experimental arms.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Opioid administration in control group
Description: Elective surgery in radical open abdominal prostatectomy. Opioid titration is guided by clinical signs in the control group.
Study: NCT01544855

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids
Description: Participants will take 700 mg/d of EPA and 500 mg/d of DHA as ethyl esters for one month (Ocean Nutrition, Dartmouth, NS) which is about 10 times the current estimated intake of young adults (21). This corresponds to one capsule with breakfast and one capsule with diner.
Study: NCT01285986

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vein collar at the distal anastomosis
Description: Vein collar interposed at the distal anastomosis or No vein collar interposed at the distal anastomosis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vein collar at the distal anastomosis
Description: Vein collar interposed at the distal anastomosis or No vein collar interposed at the distal anastomosis
Study: NCT00672594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Sunitinib Malate 50mg capsule by mouth once daily for 4 weeks
Study: NCT03500211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidoderm 5 % Topical Patch
Description: Lidocaine patch after cesarean section delivery.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Topical Patch
Description: Sham patch after cesarean section delivery.
Study: NCT00059631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (Novantrone)
Description: Starting dose of 3 mg/m\^2, four weekly intravenous injections (on Days 1, 8, 15 and 22) over eight 5 week cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib (PS-341)
Description: Starting Dose of 1.4 mg/m\^2, four weekly intravenous injections (on Days 1, 8, 15, and 22) over eight 5 week cycles.
Study: NCT04093687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endoscopist's training
Description: The training session will be divided into two parts: theoretical and practical. Trainees will be blinded to the criterion of being chosen due to their performance status.~During the first, theoretical part, the body of research on the phenomenon of colonoscopy pain will be presented. Aspects on how to deliver a painless colonoscopy (patient characteristics, insertion technique, endoscope characteristics, non-technical skills, additional manoeuvres) will be discussed. This part will be based on the findings from Phase I.~The second, practical part of the training, will consist of a one-day session of 7 colonoscopies. Participants will be matched with each other. Each participant, will perform one colonoscopy with an oversight of a matched partner, then in turn oversee the colonoscopy of another participant. The rest of the participants will observe a live transmission of each colonoscopy in a separate room, with a commentary from study coordinator.
Study: NCT00649818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam Tablets 2 mg
Description: 2mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ativan Tablets 2 mg
Description: 2mg, single dose fasting
Study: NCT01554826

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Split Vaccine
Description: 0.25ml, two doses (540 subjects were randomly assigned to receive the first dose, among them, 515 subjects received a boost dose); two doses were assigned to be vaccinated 4 weeks apart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Influenza Vaccine
Description: 0.25ml, two doses (270 subjects were randomly assigned to receive the first dose; among them, 263 subjects received a boost dose); two doses was administrated at 4 weeks apart
Study: NCT03737565

Intervention type: DEVICE
Intervention: Optimax stent®
Description: Percutaneous coronary intervention with Optimax stent®
Study: NCT01775436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAmily-CEntered Advance Care Planning
Description: Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care \& prepare the surrogate to be able to fully represent the patient's wishes.~Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FAmily-CEntered Advance Care Planning
Description: Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care \& prepare the surrogate to be able to fully represent the patient's wishes.~Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Living Control
Description: Session 1: Developmental History: Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Control
Description: Session 1: Developmental History: Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention.
Study: NCT01462318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 5 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 200 mg
Study: NCT03006588

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-FNA for RPLN in NPC patients
Description: An EUS probe was introduced to nasopharynx and the retropharyngeal space (RPS) were scanned. The suspicious recurrent RPLN, which was characterized as (1) roughly round and homogeneously hypo-echoic lesion in RPS; (2) located anterior to the carotid sheath which contained the internal carotid artery (ICA) and the internal jugular vein (IJV). Subsequently, guiding by EUS, a dedicated 22G needle was used to puncture into the enlarged RPLN, then the aspiration was conducted The entire EUS-FNA procedure was repeated at least three times till the satisfied strip tissue was obtained. The obtained tissue samples were sent for pathologic detection and the supernatant fluid was for thinprep cytologic test (TCT).
Study: NCT03387215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214
Description: Oral
Study: NCT01462318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-warfarin
Description: 10 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin K
Description: 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: 30 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB019 (Daclizumab)
Description: 150 mg in 1 ml PFS
Study: NCT00725114

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetrodotoxin
Description: 30 µg twice daily for 4 days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mL subcutaneous injection twice daily for 4 days
Study: NCT01103622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Oral tablet bd, step-wise increased dosage
Study: NCT03387215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-214
Description: Oral

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral